Molecular Profiling for Precision Medicine in Adrenocortical Carcinoma: Real-World Data From the French Network ENDOCAN-COMETE
JCO Precision Oncology · 2026-11 · 10 (11)
DOI: 10.1200/po-25-00839 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-11. Verfasst von Simon Lemaire und 18 weiteren Autor:innen. Beteiligte Einrichtung: Imaging Department, Endocrine Oncology, Gustave Roussy Cancer Institute, Paris-Saclay University, Villejuif, France. Hauptthemen laut MEDLINE: Adrenocortical Carcinoma, Precision Medicine, Adrenal Cortex Neoplasms. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
Purpose
Adrenocortical carcinoma (ACC) is a rare tumor with poor prognosis. Precision medicine and molecularly matched treatment (MMT) represent a new opportunity in oncology. Patients and Methods We conducted a retrospective study of patients with advanced ACC within the French ENDOCAN COMETE network from 2009 to 2022 who have been providing access to molecular profiling (MP). We investigated the benefits of the MMT strategy in terms of response according to RECIST, median progression-free survival (PFS), overall survival (OS), and growth modulation index (GMI).
Results
We enrolled 78 patients with ACC who underwent MP of the primary tumor in 41 patients. Most patients had metastasis at diagnosis, with at least one GRAS criterion. P53 alteration and activation of the Wnt/β-catenin pathway were the most frequent genetic alterations. No mutations were found in 20.5% of patients' tumors. The microsatellite instability phenotype was present in two cases. The median OS from the date of first metastasis was 33.3 months (95% CI, 24.7 to 56.2) with most patients receiving platinum-based chemotherapy and mitotane as first-line therapy. Twelve patients were treated with MMT as a second- or third-line therapy. An objective response rate was observed in two patients with a complete response under immunotherapy. The median PFS with MMT was 2.5 months. The mean GMI was 1.02, above 1.3 in three patients (4%).
Conclusion
Molecular alteration–based precision medicine is associated with potential antitumor benefits in a limited subset of patients with ACC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Imaging Department, Endocrine Oncology, Gustave Roussy Cancer Institute, Paris-Saclay University, Villejuif, France.
- Gustave Roussy Cancer Institute, Paris-Saclay University, DITEP, Villejuif, France.
- Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.
- Department of Endocrinology, Centre Hospitalier Régional Universitaire de Lille, Lille, France.
- Department of Endocrinology, Haut-Lévêque Hospital, Bordeaux University, Pessac, France.
- Department of Medical Oncology, CHU de Nantes-Hôpital Laennec Saint-Herblain, Nantes, France.
ORCID-Profile: Simon Lemaire, Grégoire Marret, Alexandre Lugat, Christophe Sajous, Helene Lassolle, Christine Do Cao, Antoine Italiano, Christophe Massard, Ségolène Hescot
Zitieren
APA
Lemaire, S., Marret, G., Moog, S., Jannin, A., Haissaguerre, M., Lugat, A., Sajous, C., Laboureau, S., Eas, F., Lassolle, H., Drui, D., Tabarin, A., Cao, C. D., Hadoux, J., Libé, R., Italiano, A., Massard, C., Baudin, É., & Hescot, S. (2026). Molecular Profiling for Precision Medicine in Adrenocortical Carcinoma: Real-World Data From the French Network ENDOCAN-COMETE. JCO Precision Oncology, 10(11). https://doi.org/10.1200/po-25-00839
Vancouver
Lemaire S, Marret G, Moog S, Jannin A, Haissaguerre M, Lugat A, et al. Molecular Profiling for Precision Medicine in Adrenocortical Carcinoma: Real-World Data From the French Network ENDOCAN-COMETE. JCO Precision Oncology. 2026;10(11). doi:10.1200/po-25-00839
BibTeX
@article{Lemaire2026,
author = {Lemaire, Simon and Marret, Grégoire and Moog, Sophie and Jannin, Arnaud and Haissaguerre, Magalie and Lugat, Alexandre and Sajous, Christophe and Laboureau, Sandrine and Eas, Florence and Lassolle, Helene and Drui, Delphine and Tabarin, Antoine and Cao, Christine Do and Hadoux, Julien and Libé, Rossella and Italiano, Antoine and Massard, Christophe and Baudin, Éric and Hescot, Ségolène},
title = {Molecular Profiling for Precision Medicine in Adrenocortical Carcinoma: Real-World Data From the French Network ENDOCAN-COMETE},
journal = {JCO Precision Oncology},
year = {2026},
volume = {10},
number = {11},
doi = {10.1200/po-25-00839}
}
EUVIMED